Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Transform your wealth with Omega. Exclusive consultation awaits.Schedule Meeting!
Schedule Meeting!
Biocon is currently trading at Rs. 243.50, up by 1.50 points or 0.62% from its previous closing of Rs. 242.00 on the BSE.
The scrip opened at Rs. 245.00 and has touched a high and low of Rs. 247.60 and Rs. 240.50 respectively. So far 1,01,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 390.05 on 27-Apr-2011 and a 52 week low of Rs. 229.10 on 29-Mar-2012.
Last one week high and low of the scrip stood at Rs. 247.60 and Rs. 232.40 respectively. The current market cap of the company is Rs. 4,870.00 crore.
The promoters holding in the company stood at 60.91% while Institutions and Non-Institutions held 13.95% and 25.13% respectively.
Biocon, Asia's Premier Biotechnology Company has inaugurated its state of the art integrated Research & Development (R&D) centre in Bangalore. Biocon Research Center (BRC), spread across 200,000 square feet, is aimed at pursuing world class research on biologics that will address unmet medical needs.
As a biotechnology research centre with multi-disciplinary capabilities in Molecular Biology, Biologics Process Sciences, Formulation Research and Preclinical & Clinical Development, BRC is a first- of- its kind facility in South-East Asia. The centre is also equipped with cutting edge instrumentation for extensive molecular and functional characterization of Biologics.
A team of over 300 scientists based at BRC housed in Biocon Park, will be engaged in cutting edge Biologics research. The company aims to attract outstanding scientists from the best institutes around the world and engage with international thought leaders as well as participate in technical programs as an effective way to enable innovation through knowledge sharing.
An independent quality group at BRC will ensure compliance to Good Laboratory Practices and International regulatory guidelines for developing ‘best in class’ biologics and biosimilars.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1849.05 |
| Dr. Reddys Lab | 1274.25 |
| Cipla | 1553.20 |
| Lupin | 2184.00 |
| Zydus Lifesciences | 1001.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
